Clicky

Critical Outcome Technologies Inc(COTQF)

Description: Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.


Keywords: Cancer Biopharmaceutical Chemical Compounds Tumor Treatment Of Cancer Breast Cancer Antineoplastic Drugs Kras Metastatic Breast Cancer P53 Tumor Suppressor Genes Tumor Suppressor Eribulin

Home Page: www.cotingapharma.com

The Canadian Venture Building
Toronto, ON M5C 1P1
Canada
Phone:


Officers

Name Title
Ms. Alison D. Silva MA, MS CEO, Pres & Director
Dr. Richard T. Ho Chief Scientific Officer
Mr. Victor Hugo C.M.A., CPA Chief Financial Officer
Mr. Paul Papi VP of Investor Relations

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 7.5533
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: April
Full Time Employees: 0
Back to stocks